Last updated: June 6, 2026
NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) supply chain is typically organized around (1) API and intermediate sourcing (where applicable), (2) ring-manufacturing and sterilization/filling under cGMP by a contract manufacturer or an affiliate of the marketing authorization holder, and (3) secondary packaging, labeling, and distribution logistics. In the absence of specific, citable sourcing documents (Orange Book supplier listings are not published; FDA records are not routinely indexed by supplier), a complete supplier map cannot be produced from the information provided.
What companies supply the active pharmaceutical ingredient for NuvaRing?
NuvaRing uses etonogestrel and ethinyl estradiol. Supplier identification for those APIs depends on the exact commercial lots and the labeling/DMF cross-references tied to the FDA submission for the specific NDA/RLD product. Without those specific, citable linkage records for the NuvaRing submission, no definitive supplier list can be stated.
Which manufacturers produce etonogestrel API for branded vaginal rings?
API suppliers for etonogestrel are typically multiple across geographies. Assigning specific companies to NuvaRing without lot-level or regulatory cross-reference evidence would be speculative.
Which manufacturers produce ethinyl estradiol API for NuvaRing?
Same constraint applies for ethinyl estradiol API: multiple established producers exist, but NuvaRing-specific sourcing requires submission-linked evidence not supplied here.
Which contract manufacturers build and fill NuvaRing vaginal rings?
NuvaRing is a drug-device style product (vaginal ring) produced under cGMP with polymer processing and controlled-release filling/assembly steps. Contract manufacturing and assembly partners are typically identified in supply chain documents and regulatory submissions, not in a standalone public supplier directory.
What CDMO steps are relevant to NuvaRing manufacture?
Typical steps include polymer blending (ring matrix), molding/extrusion/casting, solvent handling (if applicable), drying, sterilization or bioburden control, in-process controls, and packaging into peel pouches or blister formats. Assigning specific CDMOs requires citable source documents tied to NuvaRing.
What packaging suppliers support NuvaRing distribution?
Secondary packaging partners (cartoning, labeling, lot coding, packaging line services) also vary by market and lot. A defensible supplier list requires packaging master data tied to the FDA-labeled product.
What is NuvaRing’s FDA regulatory status and what does it imply for suppliers?
The U.S. regulatory program for NuvaRing (NDA/RLD status, listed patents, manufacturing site listings, and OOS/OAI history) can indirectly indicate manufacturing locations, but supplier identity still requires parsing the FDA submission package and site-specific listings. Without those listings in the prompt, supplier names cannot be mapped.
What does Orange Book typically show for manufacturing sites vs suppliers?
The Orange Book lists patent information and key product identifiers. It does not provide a normalized, public “supplier roster” for API, CDMO, or packaging vendors in a way that supports a complete supplier answer.
How do to identify NuvaRing suppliers from FDA submission records?
Definitive supplier identification usually comes from:
- Facility establishment and manufacturing site names associated with the application
- DMF references for APIs (where listed) and cross-referencing to manufacturer details
- Labeler/distributor and packaging site identifiers in FDA labeling records
No submission extracts or facility listing data were provided, so a supplier list cannot be constructed.
What generic or competitor supply risks affect NuvaRing sourcing?
Without a specific NuvaRing supplier map, it is not possible to quantify substitution risks, dual-sourcing availability, lead-time exposure, or IP barriers that could constrain CDMO throughput. Supplier constraints are also often lot-specific.
Key takeaways
- A complete, accurate NuvaRing supplier list (API producers, CDMOs for ring manufacturing, and packaging/logistics partners) cannot be produced from the information supplied.
- NuvaRing sourcing must be tied to FDA application-linked facility/manufacturer listings and/or labeled product supply chain documentation to be defensible.
FAQs
- Which facilities manufacture NuvaRing in the U.S.?
- Who are the API manufacturers for etonogestrel and ethinyl estradiol used in NuvaRing?
- Do NuvaRing suppliers change by country or market authorization holder?
- How can DMFs linked to NuvaRing be used to identify API vendors?
- What CDMO capabilities (polymer molding, controlled release ring manufacture) are required for NuvaRing?
References
- FDA Orange Book (Drug Products). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-06).
